All Oncology News

When the fully human IgG4 monoclonal antibody SRK-181 was given as a monotherapy or in combination with anti–PD-1 or PD-L1 agents in patients with locally advanced or metastatic solid tumors, it was found to be generally well tolerated and to demonstrate early indications of efficacy.

Erin K. Crane, MD, MPH, describes practice-changing findings from upfront trials with niraparib and olaparib, contextualizes the significance of the manufacturer restrictions of later-line PARP inhibitors for ovarian cancer, and predicts further research efforts in this population.

Researchers at Fox Chase Cancer Center have begun recruiting for a clinical trial called PRESERVE that will evaluate the safety and efficacy of the NanoKnife System to treat patients with intermediate-risk prostate cancer.

Nirav N. Shah, MD, explains the choice to evaluate LV20.19 CAR in MCL, key efficacy and safety data from the follow-up study of this agent, and ongoing efforts to potentially expand its use across other B-cell malignancies.

Bellicum Pharmaceuticals has discontinued 2 phase 1/2 trials evaluating the safety and preliminary efficacy of the GoCAR T-cell products BPX-601 and BPX-603 in combination with rimiducid in heavily pretreated patients with advanced solid tumors following an assessment of the risk/benefit profile of the combination of BPX-601 and rimiducid.

Ripretinib has been added to the National Comprehensive Cancer Network Guidelines as a preferred regimen in the second-line treatment of patients with gastrointestinal stromal tumor who are intolerant to sunitinib.

A new understanding of pathogenesis has given rise to a promising prevention strategy for women at an average risk of developing ovarian cancer through surgical removal of the fallopian tubes, referred to as an opportunistic salpingectomy.

Improvements in graft-vs-host disease and transplant-related mortality have created a wave of hope for clinicians treating their patients with hematologic malignancies, stemming from the encouraging data seen with Orca-T and other novel therapeutics in the pipeline.

The FDA has granted an orphan drug designation to EP0042 for use as a potential therapeutic option in patients with acute myeloid leukemia with acquired resistance to FLT3 inhibitors.

Vorasidenib monotherapy elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with placebo in patients with residual or recurrent IDH1/2-mutant low-grade glioma.

Enzalutamide plus androgen deprivation therapy produced a statistically significant improvement in time to prostate-specific antigen progression compared with ADT and placebo in men with metastatic hormone-sensitive prostate cancer, meeting the primary end point of the phase 3 China ARCHES study.

Although the immune system plays a vital role in attacking tumor cells, the immune mechanisms vary from tumor to tumor, and factors in the tumor microenvironment can reduce the effectiveness of the body’s immune response.

Daryl Pritchard, PhD, discussed how recent findings highlight the importance of targeted therapy in advanced lung cancer, areas where the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology could be updated to better encapsulate real-world practice patterns, and the ways in which increased access to molecular testing can help usher in a new era of personalized medicine.

Gifts totaling $3 million will create an endowed chair in cancer informatics at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Adjuvant osimertinib and other targeted therapies, such as KRAS G12C inhibitors, could continue to change the perioperative treatment landscape in non–small cell lung cancer.

Precision medicine and personalized medicine are 2 concepts that have pushed their way to the forefront of oncology practice.

Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.

The FDA has approved nelarabine for injection for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, according to an announcement from Shorla Oncology.

The FDA has placed a clinical hold on a phase 1 trial investigating the antibody-drug conjugate XMT-2056 for the treatment of patients with advanced/recurrent solid tumors that express HER2.

Heterogeneous patterns of polycythemia vera management indicate the need for continued research in this disease and increased guideline specificity across treatment centers in Italy.

Florida Cancer Specialists & Research Institute, LLC, a consistent top performer among the 126 U.S.-based oncology practices that participated in the Center for Medicare & Medicaid Innovation Oncology Care Model, shares its results in the payment and delivery model’s final wave which ended in June 2022 in a newly released case study.

Soligenix has submitted a Type A meeting request to the FDA to discuss the contents of a refusal to file letter from the regulatory agency regarding the new drug application for synthetic hypericin for the treatment of early-stage cutaneous T-cell lymphoma.

Here are 5 tips and tricks to help you shine when the spotlight is on you.

The combination of AB011 and capecitabine/oxaliplatin was found to have a manageable safety profile and to showcase early clinical benefit when used as first-line treatment in patients with gastric cancer or gastroesophageal junction adenocarcinoma.

Kevin Raskin, MD, discusses time management, the importance of taking time off, and teaching fellows how to listen to their inner voice.

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

Precision medicine has arrived in all stages of prostate cancer care and recommendations for optimal testing and how best to leverage the results to inform clinical decisions continue to rapidly evolve.

Although the formal process of investigating a job takes time and effort, the reality is that you started interviewing for your first job on the first day of your fellowship.

Lisa M. Carey, MD, ScM, FASCO, discusses upcoming treatments that could impact standard-of-care practices and the continually evolving role of antibody-drug conjugates role in the breast cancer treatment paradigm.

IU School of Medicine alumnus Kip E. Virts, MD, has made an $8 million estate gift to support bile duct cancer research at Indiana University Melvin and Bren Simon Comprehensive Cancer Center.